Poland· PL-100308901
Cayston
A aztreonam product containing aztreonamum, registered in Poland by Gilead Sciences Ireland UC. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Aztreonam is registered in 16 of 19 countries.
Countries holding a registration under ATC J01DF01 (aztreonam), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Aztreonam · ATC J01DF01
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aztreonam costs, country by country.
Normalised to the WHO defined daily dose (0.225 g), the median price runs from $4.80 in Spain to $107.66 in Switzerland — a ×22 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Aztreonam · price per daily dose (0.225 g)
USD · FX 28 Sept 2026
- CH Switzerland$107.66
- ES Spain$4.80
The record
At a glance
URPL (Poland)- Active substance
- Aztreonamum
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Poland (PL)
- ATC code
- J01DF01
- ATC class
- Aztreonam
- Defined daily dose
- 0.225 g, Inhal
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
40 interactions on record for aztreonam.
Graded by severity as the source publishes them — 10 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aztreonam · interactions on record
40 records
- 10 moderate
- 30 info
Most severe, free to view
- Sodium picosulfateA06AB08moderate
- DicoumarolB01AA01moderate
- WarfarinB01AA03moderate
- Levonorgestrel and ethinylestradiolG03AA07moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aztreonam in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomCayston 75mg powder and solvent for nebuliser solution vialsGilead Sciences Ltd
- SpainCAYSTON 75 mg POLVO Y DISOLVENTE PARA SOLUCION PARA INHALACION POR NEBULIZADORGilead Sciences Ireland Unlimited Company
- IrelandCayston 75 mg powder and solvent for nebuliser solution.Gilead Sciences Ireland UC
- United StatesAZACTAME.R. Squibb & Sons, L.L.C.
- BelgiumAzactam 1 gLaboratoires Delbert
- FinlandAzactamLaboratoires Delbert x
- FranceAZACTAM 1 g, poudre pour solution injectable/pour perfusionLABORATOIRES DELBERT
- SwitzerlandAzactam 2 g, poudre pour solution injectable/pour perfusionLeman SKL SA
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Austria · Azactam
- Belgium · Azactam
- Spain · Azactam
- Finland · Azactam
- France · Azactam
- United Kingdom (Northern Ireland) · Aztreonam Kent Pharma Uk, Aztreonam Kent Pharma Uk Ltd
- Ireland · Azactam
- Iceland · Cayston
- Liechtenstein · Cayston
- Luxembourg · Azactam
- Norway · Azactam, Cayston
- Portugal · Azactam
- Romania · Azactam
- Sweden · Azactam
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8d7d89aa-0b01-4ab2-b329-73ab4b42e57d GET /v1/drugs/8d7d89aa-0b01-4ab2-b329-73ab4b42e57d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do nebulizacji",
"source": "urpl",
"strength": "75 mg",
"packaging": "Rp ¦ EU/1/09/543/001 ¦ 88443\n84 fiol. proszku ¦ 88 amp. 1 ml rozp.\nRp ¦ EU/1/09/543/002 ¦ 88444\n84 fiol. proszku ¦ 88 amp. 1 ml rozp. ¦ 1 zestaw Nebulizatora Altera",
"substance": "Aztreonamum 75 mg",
"common_name": "Aztreonamum",
"pl_product_id": "100308901",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about aztreonam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.